GLIBA - WeissLaw LLP Reminds GLIBA and CBMG Shareholders About Its Ongoing Investigations

PR Newswire

NEW YORK, Sept. 22, 2020

NEW YORK , Sept. 22, 2020 /PRNewswire/ --

If you own shares in any of the companies listed above and
would like to discuss our investigations or have any questions concerning
this notice or your rights or interests, please contact:

Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16 ^th Floor
New York , NY  10036
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com

GCI Liberty, Inc. (NASDAQ: GLIBA)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of GCI Liberty, Inc. (NASDAQ: GLIBA) in connection with the proposed acquisition of the company by Liberty Broadband.  Under the terms of the transaction, Series A GLIBA shareholders will receive 0.580 shares of Liberty Broadband's Series C common stock for each share of GLIBA stock they hold.  If you own GLIBA shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: http://www.weisslawllp.com/gci-liberty-inc/

Cellular Biomedicine Group, Inc. (NASDAQ: CBMG)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) in connection with the proposed interested-party acquisition of the company by a newly-formed entity consisting of CBMG's CEO Tony Liu , certain member of the company's management, and a consortium of stockholders and equity investors (the "Affiliates").  Under the terms of the acquisition agreement, CBMG shareholders will receive $19.75 in cash for each share they own.  Notably, the Affiliates consist of company insiders and other large stockholders that collectively hold approximately 51.5% of the outstanding CBMG shares and may have exerted undue influence on the board. If you own CBMG shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: http://www.weisslawllp.com/cellular-biomedicine-group-inc/

SOURCE WeissLaw LLP